Molecular Precision works with research and development teams on the structured design, representation and translation of complex biological systems — from SBOL3 implementation and nanomedicine architecture to design review and regulatory translation.
Molecular Precision works through focused, well-scoped engagements. Each begins with a specific biological system, design problem or technical question — not an abstract platform or a lengthy onboarding process. Two engagement models, both producing a concrete, structured output.
We take a single biological system, formulation or design problem and represent it as an explicit, structured design — connecting components, requirements, decisions and evidence in a machine-readable form. A focused, well-scoped piece of work with a concrete output.
For teams developing multiple biological designs or nanomedicine programmes, an ongoing engagement builds structured design into the work from the start — across SBOL3 implementation, nanomedicine architecture, traceability and regulatory translation.
Molecular Precision works with research groups, biotechnology organisations and development teams working with biological systems that have become difficult to describe, reproduce, transfer or translate.
The common problem is complexity: important relationships between biological intent, design decisions, experimental methods, specifications and evidence are no longer adequately captured by conventional documents alone.
University-linked and collaborative research groups moving from scientific exploration towards reproducible and transferable development.
We help structure biological designs, experimental knowledge and technical requirements so that critical information can move between researchers, projects and development stages without losing the reasoning behind it.
Organisations managing complex biological designs across multiple projects, teams, partners or computational systems.
This may involve adopting SBOL3, developing structured design representations, improving interoperability, establishing design traceability or creating clearer relationships between technical decisions and supporting evidence.
Research groups and biotechnology companies developing nanoparticles, delivery systems and other nanoscale therapeutic platforms.
We help teams move beyond formulation descriptions towards structured design architectures connecting therapeutic intent, biological interaction, delivery requirements, material characteristics and manufacturing specifications.
Consider a four-component SM-102 mRNA lipid nanoparticle formulation described using information available in the scientific literature. A conventional methods description might specify the lipid components, their molar proportions, the aqueous and organic phases and the principal mixing conditions.
This may be sufficient to communicate the broad experimental method. It does not necessarily provide a complete representation of the design.
A conventional description may tell us:
But many relationships remain implicit.
The method describes what was done. It does not necessarily describe why the system is designed that way.
Within the Molecular Precision approach, the formulation can instead be represented as a connected design system.
The therapeutic objective establishes requirements at the clinical and biological levels. Those requirements inform the delivery architecture. The delivery architecture creates requirements for the nanomaterial. Individual components and material characteristics can then be connected to their functional roles. Manufacturing parameters and analytical specifications provide the physical implementation of that design.
A component such as SM-102 is therefore more than a name within a molar ratio. It becomes a defined design element with an identity, function and relationships to other parts of the system.
Likewise, particle size is more than a reported measurement. It can be represented as a characteristic connected to biological behaviour, delivery requirements, process parameters, analytical methods and specification limits.
The result is a traceable architecture:
Instead of asking only “How was this formulation made?” we can also ask:
Molecular Precision works with research and development teams on the structured design, representation and translation of complex biological systems. Its work includes SBOL3 implementation, biological design representation, nanomedicine architecture, design review, traceability, specification development and regulatory translation.
Molecular Precision works with translational research groups, biotechnology and applied-research organisations, and nanomedicine development teams working with biological systems that have become difficult to describe, reproduce, transfer or translate.
The common problem is complexity: important relationships between scientific intent, design decisions, experimental methods, specifications and evidence are no longer adequately captured by conventional documents alone.
A Structured Design Pilot is a focused engagement in which a single biological system, formulation or design problem is converted into an explicit structured design.
The work can include a machine-readable representation, mapping of components and relationships, traceability between requirements and evidence, and identification of ambiguities or gaps in the existing description.
The current indicative range published by Molecular Precision is £3,000–£8,000, depending on the scope and complexity of the system or design problem.
Yes. Continuous Design Support is available for teams working across multiple biological designs or nanomedicine programmes. It can incorporate structured design representation, SBOL3 implementation, nanomedicine architecture, design traceability, evidence linking and support for specification and regulatory documentation.
The current indicative range for Continuous Design Support is £4,000–£10,000 per month, with the scope determined by the projects, programmes and technical support required.
Yes. SBOL3 implementation is one of the areas covered by Molecular Precision’s structured biological-design work. This can include representing biological designs in a machine-readable form, defining components and relationships, improving interoperability and establishing clearer design traceability.
Yes. An engagement can begin with an existing biological system, formulation, published method or technical design.
The purpose is not necessarily to redesign the underlying science. It can instead make existing components, functions, requirements, assumptions, evidence and specifications explicit and identify areas where important relationships remain undocumented.
Yes. Nanomedicine development is one of Molecular Precision’s principal areas of work. The Nanomedicine Design Stack provides a structured architecture connecting therapeutic intent, biological interaction, delivery architecture, nanomaterial architecture and manufacturing specification.
Molecular Precision provides regulatory translation rather than acting as a substitute for specialist regulatory or legal advice. The work focuses on connecting scientific intent and biological design to structured specifications, evidence architectures and technical documentation that can support development, review and regulatory interaction.
Outputs depend on the project but can include structured machine-readable biological designs, component and relationship mappings, design requirements, traceability structures, evidence mappings, design reviews, specifications and technical documentation.
The emphasis is on producing a concrete structured output rather than an abstract strategy exercise.
An engagement begins with a focused discussion of the biological system, design problem or technical challenge. A short initial conversation is normally used to establish whether Molecular Precision is an appropriate fit and whether the problem is suitable for a Structured Design Pilot, ongoing support or another defined engagement.
Engagements can begin with a focused discussion of the biological system, design problem or technical challenge.
This may lead to an SBOL3 implementation, structured biological design project, nanomedicine design review, technical framework or regulatory translation engagement.
A short initial conversation is usually sufficient to establish whether Molecular Precision is an appropriate fit.
Discuss a project →